NovoCure (NVCR) Current Assets (2014 - 2026)

NovoCure has disclosed Current Assets across 13 years of filings, most recently posting $631.7 million for Q1 2026.

• Current Assets for Q1 2026 came in at $631.7 million, down 42.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $631.7 million (down 42.01% YoY), and the FY2025 annual result was $646.7 million, down 41.56% from the prior year.
• Current Assets came in at $631.7 million for Q1 2026 at NovoCure, down from $646.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q3 2025 to a low of $631.7 million in Q1 2026.
• The 5-year median for Current Assets is $1.1 billion (2023), against an average of $1.0 billion.
• Across the five-year window, Current Assets increased 9.55% in 2025 and tumbled 42.01% in 2026, its largest moves.
• NovoCure's Current Assets stood at $1.1 billion in 2022, then slipped by 6.94% to $1.0 billion in 2023, then rose by 6.98% to $1.1 billion in 2024, then sank by 41.56% to $646.7 million in 2025, then slipped by 2.33% to $631.7 million in 2026.
• The last three Current Assets figures came in at $631.7 million (Q1 2026), $646.7 million (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.